AU2002218890A1 - A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell - Google Patents

A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell

Info

Publication number
AU2002218890A1
AU2002218890A1 AU2002218890A AU1889002A AU2002218890A1 AU 2002218890 A1 AU2002218890 A1 AU 2002218890A1 AU 2002218890 A AU2002218890 A AU 2002218890A AU 1889002 A AU1889002 A AU 1889002A AU 2002218890 A1 AU2002218890 A1 AU 2002218890A1
Authority
AU
Australia
Prior art keywords
expression
yeast
making
recombinant protein
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218890A
Inventor
Desire Jose Collen
Yves Laroche
Nubuo Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thromb X NV
Original Assignee
Thromb X NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0031196A external-priority patent/GB0031196D0/en
Priority claimed from GB0116690A external-priority patent/GB0116690D0/en
Priority claimed from GB0116702A external-priority patent/GB0116702D0/en
Application filed by Thromb X NV filed Critical Thromb X NV
Publication of AU2002218890A1 publication Critical patent/AU2002218890A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vectors for the expression in yeast of mammalian plasminogen derivatives such as microplasminogen and miniplasminogen are presented. Methods for expression of these proteins in a methylotrophic yeast expression system are disclosed as well as the activation and stabilisation of the recombinant proteins. The proteins of this invention are used In the treatment of focal cerebral ischemic infarction and other thrombotic diseases.
AU2002218890A 2000-12-21 2001-12-20 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell Abandoned AU2002218890A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0031196 2000-12-21
GB0031196A GB0031196D0 (en) 2000-12-21 2000-12-21 Recombinant human plasminogen and plasmin: methods for high yield production stabilization and use for treatment
GB0116702 2001-07-09
GB0116690 2001-07-09
GB0116690A GB0116690D0 (en) 2001-07-09 2001-07-09 Human plasminogen and plasmin
GB0116702A GB0116702D0 (en) 2001-07-09 2001-07-09 Human plasminogen and plasmin
PCT/BE2001/000217 WO2002050290A1 (en) 2000-12-21 2001-12-20 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell

Publications (1)

Publication Number Publication Date
AU2002218890A1 true AU2002218890A1 (en) 2002-07-01

Family

ID=27256020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218890A Abandoned AU2002218890A1 (en) 2000-12-21 2001-12-20 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell

Country Status (11)

Country Link
US (1) US7445775B2 (en)
EP (1) EP1343903B1 (en)
JP (2) JP4047170B2 (en)
AT (1) ATE378413T1 (en)
AU (1) AU2002218890A1 (en)
CY (1) CY1107866T1 (en)
DE (1) DE60131450T2 (en)
DK (1) DK1343903T3 (en)
ES (1) ES2296705T3 (en)
PT (1) PT1343903E (en)
WO (1) WO2002050290A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998121B2 (en) * 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
MXPA04007585A (en) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms.
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
KR100595864B1 (en) * 2004-01-27 2006-06-30 재단법인 목암생명공학연구소 Transformed Saccharomyces cerevisiae and production method of LK8 protein using the same
WO2005078109A2 (en) 2004-02-11 2005-08-25 Biolex, Inc. Expression of plasminogen and microplasminogen in duckweed
DK1740698T3 (en) * 2004-04-22 2010-10-25 Talecris Biotherapeutics Inc Recombinant modified plasmin
CN100368524C (en) * 2005-05-17 2008-02-13 上海大学 High density fermentation method for GS115/PFK-K5
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
BRPI0819780B1 (en) 2007-11-29 2023-01-24 Grifols Therapeutics Inc POLYNUCLEOTIDE AND METHOD FOR PRODUCING ONE OR MORE RECOMBINANT PLASMIN POLYPEPTIDES
RU2495131C2 (en) * 2008-02-19 2013-10-10 Байокон Лимитид Method to produce recombinant insulin glargine
US8617863B2 (en) 2008-06-04 2013-12-31 Grifols Therapeutics Inc. Composition, method, and kit for preparing plasmin
PT2403865E (en) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Methods for preparing plasminogen
RU2564131C2 (en) 2009-07-10 2015-09-27 ТромбоДженикс НВ Versions of plasminogen and plasmin
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
BR112013017172A2 (en) 2011-01-05 2016-10-11 Thrombogenics Nv plasminogen and plasmin variants
KR20140064841A (en) 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. Plasminogen and plasmin variants
CN110066783B (en) * 2019-05-16 2021-07-13 重庆派金生物科技有限公司 Preparation method of microplasmin without self-cutting form
CN113355309B (en) * 2021-08-10 2021-11-05 迈威(上海)生物科技股份有限公司 Process for preparing recombined truncated human fibrinolysin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
JPH05500748A (en) * 1989-05-01 1993-02-18 ザ　ユニバーシティ　オブ　ノートル　ダム　デュ　ラック Methods and substances for expressing human plasminogen in eukaryotic cell systems
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
DE69934595T2 (en) * 1998-09-29 2007-10-04 Leuven Research & Development V.Z.W. USE OF COMPOUNDS REDUCING ALPHA2 ANTIPLASMINE IN VIVO FOR PREPARING A COMPOSITION FOR TREATING ISCHEMIC ATTACKS

Also Published As

Publication number Publication date
JP4250660B2 (en) 2009-04-08
ES2296705T3 (en) 2008-05-01
DK1343903T3 (en) 2008-03-10
JP2007195558A (en) 2007-08-09
ATE378413T1 (en) 2007-11-15
DE60131450D1 (en) 2007-12-27
US7445775B2 (en) 2008-11-04
WO2002050290A1 (en) 2002-06-27
DE60131450T2 (en) 2008-10-16
JP2004526427A (en) 2004-09-02
EP1343903B1 (en) 2007-11-14
JP4047170B2 (en) 2008-02-13
US20040071676A1 (en) 2004-04-15
EP1343903A1 (en) 2003-09-17
CY1107866T1 (en) 2013-06-19
PT1343903E (en) 2008-02-18

Similar Documents

Publication Publication Date Title
AU2002218890A1 (en) A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
WO1997033996A3 (en) Human bikunin
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005071088A3 (en) Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
BRPI0411112A (en) heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein
WO1997041824A3 (en) Antiangiogenic peptides derived from plasminogen
DK1204738T3 (en) Process for reducing foam formation during cultivation of a microorganism
DK1530637T3 (en) Carlsberg subtilisin proteins with reduced immunogenicity
PL1675956T3 (en) Minimal dna sequence acting as a chromatin insulator and its use in protein expression
WO2002046430A3 (en) Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2003222717A1 (en) Streptavidin-binding peptide
PT1025245E (en) RAPID CREATION OF MAMMARIAN STABLE CELL LINES PRODUCING HIGH RECOMBINANT PROTEIN TITLES
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
HK1047128A1 (en) Production of proteins
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU2002345213A1 (en) Expression vectors encoding bacteriophage signal peptides
FI951633A (en) Increased production of secreted proteins in eukaryotic recombinant cells
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002320773A1 (en) Vector for site-specific integration of heterologous dna sequences into the rdn a sites of methylotrophic yeasts
AU2001240540A1 (en) Method for the manufacture of recombinant trypsin
MXPA03010785A (en) Protease deficient caulobacter.
WO2002006464A3 (en) Large scale expression and purification of recombinant proteins
AU2003226907A1 (en) Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
WO2023043978A3 (en) Caix targeting il-12 fusion proteins and methods of use thereof